2. Stem Cell/Wnt MAPK/ERK Pathway Autophagy Apoptosis
  3. Organoid p38 MAPK Autophagy Apoptosis
  4. SB 202190

SB 202190 is a selective p38 MAP kinase inhibitor with IC50s of 50 nM and 100 nM for p38α and p38β2, respectively. SB 202190 binds to the ATP pocket of the active recombinant human p38 kinase with a Kd of 38 nM. SB 202190 has anti-cancer activity and rescued memory deficits. SB202190 induces autophagy.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

CAS 番号 : 152121-30-7

容量 価格（税別） 在庫状況 数量
>無料サンプル (0.1 - 0.2 mg)   今すぐ申し込む  
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
 USD 66 在庫あり
Solution
10 mM * 1 mL in DMSO USD 66 在庫あり
Solid
50 mg $60 在庫あり
100 mg $106 在庫あり
200 mg $198 在庫あり
500 mg   お問い合わせ  
1 g   お問い合わせ  

* アイテムを追加する前、数量をご選択ください

This product is a controlled substance and not for sale in your territory.

カスタマーレビュー

Based on 134 publication(s) in Google Scholar

Other Forms of SB 202190:

SB 202190 関連抗体

Top Publications Citing Use of Products

顧客検証

Cell Proliferation/Viability Assay
WB
RT-PCR
IF

    SB 202190 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Apr 7;16(1):3319.  [Abstract]

    After treatment with 20 μM SB202190 for 2 h followed by heat stress for 1 h, KYSE 70 and KYSE150 cells were subjected to Western blot analysis.

    SB 202190 purchased from MedChemExpress. Usage Cited in: NPJ Biofilms Microbiomes. 2024 Jan 20;10(1):5.  [Abstract]

    Percentage cell proliferation of CT26 cells treated with MEK inhibitor U0126-EtOH (HY-12031; 25 µM), JNK inhibitor SP600125 (HY-12041; 25 µM), P38/MAPK inhibitor SB202190 (HY-10295; 20 µM), GSK3β inhibitor TWS119 (HY-10590; 20 µM), or AR-A014418 (HY-10512; 20 µM), and vehicle or Cori.ST1911. Cell OD was measured using the CCK8 method and normalised to cell proliferation of the control. Inhibitor treatment started 4 h before Cori.ST1911 treatment. Data are represented as mean ± SEM (n = 3 independent tests), analysed by one-way analysis of variance (ANOVA) with Bonferroni’s post-hoc test. n.s., no significance.

    SB 202190 purchased from MedChemExpress. Usage Cited in: Mol Cancer. 2023 Jan 24;22(1):17.  [Abstract]

    Representative images (top and middle rows) of organoids cultured for 3d in basic media with/without addition of FGF2 or the indicated inhibitors. Bottom row: Immunofluorescence staining of the frozen section of the organoids. U0126 (10 μM), PD184352 (1 μM), cytochalasin D (1 μM) and SB202190 (10 μM).

    SB 202190 purchased from MedChemExpress. Usage Cited in: Nat Metab. 2023 Mar;5(3):481-494.  [Abstract]

    Mt2gene expression in beige adipocytes treated with indicated compounds (50 ng/mL TNF, 2 μM BMS345541, 1 μM SCH772984, 5 μM SB202190 and 5 μM SP600125; n = 4 biological independent samples).

    SB 202190 purchased from MedChemExpress. Usage Cited in: Acta Biochim Biophys Sin (Shanghai). 2019 Apr 1;51(4):365-374.  [Abstract]

    MAPKs inhibitors suppress LPS-induced COX-2 expression and AKT1 phosphorylation. RAW264.7 cells are pretreated for 1 h with U0126, SB202190, SP600125 alone, or all the three inhibitors, respectively, and then exposed to 40 ng/ml LPS for 30 min or 12 h. The phosphorylated protein kinases and COX-2 expression are detected by western blot analysis using their corresponding antibodies.

    SB 202190 purchased from MedChemExpress. Usage Cited in: J Cell Biochem. 2019 Mar;120(3):3898-3910.  [Abstract]

    Cells pretreated with SP600125 show a decreased proapoptotic Bax expression and increase antiapoptotic Bcl-2 formation when JNK pathway is blocked. Inhibition of p38 by SB202190 significantly enhanced Bcl-2 expression. Pretreatment with BAY 11-7082 to inhibit NF‐κB markedly enhance Baxm and decrease Bcl-2 expression compared with the ACR-treated group.

    SB 202190 purchased from MedChemExpress. Usage Cited in: J Neuroinflammation. 2018 Oct 19;15(1):291.  [Abstract]

    Blocking the three MAPK signaling pathways through specific inhibitors (U0126; SB202190; and SP600125) significantly decrease the infection-induced neuroinflammatory response via real-time PCR analysis.

    SB 202190 purchased from MedChemExpress. Usage Cited in: J Neuroinflammation. 2018 Oct 19;15(1):291.  [Abstract]

    Blocking the three MAPK signaling pathways through specific inhibitors (U0126; SB202190; and SP600125) significantly decrease the infection-induced neuroinflammatory response via real-time PCR analysis.

    SB 202190 purchased from MedChemExpress. Usage Cited in: Int J Mol Med. 2017 Jan;39(1):71-80.  [Abstract]

    Inhibition of p38 expression enhances the promoting effect of miR-214 on the adipocyte differentiation of bone marrow-derived mesenchymal stem cells (BMSCs) following the overexpression of miR-214. p-p38 protein expression decreases following treatment with p38 inhibitor, as shown by (A) western blot analysis, and (B) statistical analysis of p-p38 protein expression.

    SB 202190 purchased from MedChemExpress. Usage Cited in: Oxid Med Cell Longev. 2017:2017:7426458.  [Abstract]

    Representative immunoblot analysis of p53, p16, p21, and retinoblastoma protein (Rb) in NP cells.

    SB 202190 purchased from MedChemExpress. Usage Cited in: China Biotechnology. 2017, 37(12): 40-48.

    The Western blot analysis of HOG1 and Phospho-HOG1.

    SB 202190 purchased from MedChemExpress. Usage Cited in: EBioMedicine. 2015 Nov 19;2(12):1944-56.  [Abstract]

    SW620 xenograft tumors are treated with SB202190 and OSI027 individually or in combination. The effect on signaling by p38 (P-MK2 and P-Hsp27) and mTOR (P-S6K1 and P-AKT) is analyzed by immunoblot. SB202190 achieves on-target inhibition by diminishes phosphorylation of MK2 and Hsp27. OSI-027 blocks signaling by both mTORC1 and mTORC2 by decreases phosphorylation of S6K1 and AKT. When SB202190 and OSI-027 are used in combination, all three kinases, p38, mTORC1 and mTORC2 are potently inhibited.

    p38 MAPK アイソフォーム固有の製品をすべて表示:

    すべてのアイソフォームを表示
    p38 MAPK Akt1 p38α p38β MAPK13 p38δ p38γ

    • 生物活性

    • 純度とドキュメンテーション

    • 参考文献

    • カスタマーレビュー

    製品説明

    SB 202190 is a selective p38 MAP kinase inhibitor with IC50s of 50 nM and 100 nM for p38α and p38β2, respectively. SB 202190 binds to the ATP pocket of the active recombinant human p38 kinase with a Kd of 38 nM. SB 202190 has anti-cancer activity and rescued memory deficits[1][2]. SB202190 induces autophagy[3].

    IC50 & Target[1]

    p38α

    50 nM (IC50)

    p38β2

    100 nM (IC50)

    Cellular Effect
    Cell Line Type Value Description References
    Astrocyte EC50
    64.8 3
    Compound: SB-202190
    Antiproliferative activity against mouse astrocyte cells by MTT assay
    Antiproliferative activity against mouse astrocyte cells by MTT assay
    		[PMID: 17417631]
    Astrocyte EC50
    64.8 3
    Compound: SB-202190
    Antiproliferative activity against mouse astrocyte cells by MTT assay
    Antiproliferative activity against mouse astrocyte cells by MTT assay
    		[PMID: 17417631]
    Astrocyte EC50
    64.8 3
    Compound: SB-202190
    Antiproliferative activity against mouse astrocyte cells by MTT assay
    Antiproliferative activity against mouse astrocyte cells by MTT assay
    		[PMID: 17417631]
    Medulloblastoma cell EC50
    3.006 3
    Compound: SB-202190
    Antiproliferative activity against mouse medulloblastoma cells harboring heterozygous ptch1 gene by MTT assay
    Antiproliferative activity against mouse medulloblastoma cells harboring heterozygous ptch1 gene by MTT assay
    		[PMID: 17417631]
    Medulloblastoma cell EC50
    3.006 3
    Compound: SB-202190
    Antiproliferative activity against mouse medulloblastoma cells harboring heterozygous ptch1 gene by MTT assay
    Antiproliferative activity against mouse medulloblastoma cells harboring heterozygous ptch1 gene by MTT assay
    		[PMID: 17417631]
    RAW264.7 IC50
    16 3
    Compound: SB202190
    Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production incubated for 10 mins prior to LPS-challenge measured after 18 hrs by Griess method
    Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production incubated for 10 mins prior to LPS-challenge measured after 18 hrs by Griess method
    		[PMID: 22831798]
    RAW264.7 IC50
    16 3
    Compound: SB202190
    Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production incubated for 10 mins prior to LPS-challenge measured after 18 hrs by Griess method
    Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production incubated for 10 mins prior to LPS-challenge measured after 18 hrs by Griess method
    		[PMID: 22831798]
    Medulloblastoma cell EC50
    3.006 3
    Compound: SB-202190
    Antiproliferative activity against mouse medulloblastoma cells harboring heterozygous ptch1 gene by MTT assay
    Antiproliferative activity against mouse medulloblastoma cells harboring heterozygous ptch1 gene by MTT assay
    		[PMID: 17417631]
    RAW264.7 IC50
    16 3
    Compound: SB202190
    Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production incubated for 10 mins prior to LPS-challenge measured after 18 hrs by Griess method
    Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production incubated for 10 mins prior to LPS-challenge measured after 18 hrs by Griess method
    		[PMID: 22831798]
    体外実験

    SB 202190 (0-10 μM; 0-72 hours) attenuates growth of a subgroup of CRC cell lines such as RKO, CACO2 and SW480 in a dose- and time-dependent manner[1].
    SB 202190 strongly inhibited colony formation and anchorage-independent growth (10 μM for 7–10 days) and elevated apoptotic cell death (10 μM for 72 h) in this same subset of CRC lines (RKO, CACO2 and SW480)[2].
    In RKO, CACO2 and SW480 cells, SB202190 (10 μM; 2 hours) abrogates phosphorylation of S6K1(T389) and S6(S235/236), but not AKT(S473), indicating that p38i selectively blocks mTORC1 signaling[2].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    SB 202190 関連抗体
    体内実験

    SB 202190 (5 mg/kg; intraperitoneal injection; daily for 10-12 days) shows inhibition of tumor cell survival and tumor growth[2].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Animal Model: 4-week-old female BALB/c nude mice (bearing SW480 and RKO xenograft tumors)[2]
    Dosage: 5 mg/kg
    Administration: Intraperitoneal injection; daily for 10-12 days
    Result: Inhibition of tumor cell survival and tumor growth.
    分子量

    331.34

    分子式

    C20H14FN3O
    CAS 番号
    Appearance

    Solid

    Color

    Off-white to yellow

    SMILES

    FC1=CC=C(C2=C(C3=CC=NC=C3)NC(C4=CC=C(O)C=C4)=N2)C=C1
    輸送条件

    Room temperature in continental US; may vary elsewhere.
    保管条件
    Powder -20°C 3 years
      4°C 2 years
    In solvent -80°C 6 months
      -20°C 1 month
    溶剤 & 溶解度
    体外: 

    DMSO : 100 mg/mL (301.80 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

    Preparing
    Stock Solutions
    Concentration Solvent Mass 1 mg 5 mg 10 mg
    1 mM 3.0180 mL 15.0902 mL 30.1805 mL
    5 mM 0.6036 mL 3.0180 mL 6.0361 mL
    10 mM 0.3018 mL 1.5090 mL 3.0180 mL
    View the Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

    • Molarity Calculator

    • Dilution Calculator

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass
    =
    Concentration
    ×
    Volume
    ×
    Molecular Weight *

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    一般には略語で表示されます：C1V1 = C2V2

    濃度 （開始）

    C1

    ×
    体積 （開始）

    V1

    =
    濃度 （終了）

    C2

    ×
    体積 （終了）

    V2

    体内:

    Select the appropriate dissolution method based on your experimental animal and administration route.

    For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
    To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
    The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

    • Protocol 1

      Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

      Solubility: ≥ 2.08 mg/mL (6.28 mM); Clear solution

      This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

      Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
    • Protocol 2

      Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

      Solubility: ≥ 2.08 mg/mL (6.28 mM); Clear solution

      This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

      Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.

    For the following dissolution methods, please prepare the working solution directly. It is recommended to prepare fresh solutions and use them promptly within a short period of time.
    The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

    • Protocol 1

      Add each solvent one by one:  15% Cremophor EL    85% Saline

      Solubility: 12.5 mg/mL (37.73 mM); Suspended solution; Need ultrasonic

    In Vivo Dissolution Calculator
    Please enter the basic information of animal experiments:

    Dosage

    mg/kg

    Animal weight
    (per animal)

    g

    Dosing volume
    (per animal)

    μL

    Number of animals

    Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
    Please enter your animal formula composition:
    %
    DMSO +
    % 
    +
    %
    Tween-80 +
    %
    Saline
    Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
    The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
    Calculation results:
    Working solution concentration: mg/mL
    Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).
    The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
    Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
     If the continuous dosing period exceeds half a month, please choose this protocol carefully.
    Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
    純度とドキュメンテーション

    純度: 99.89%

    COA (251 KB) HNMR (195 KB) LCMS (120 KB) Elemental Analysis Report (109 KB)

    取扱説明書 (2659 KB)
    参考文献

    Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

    Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
    DMSO 1 mM 3.0180 mL 15.0902 mL 30.1805 mL 75.4512 mL
    5 mM 0.6036 mL 3.0180 mL 6.0361 mL 15.0902 mL
    10 mM 0.3018 mL 1.5090 mL 3.0180 mL 7.5451 mL
    15 mM 0.2012 mL 1.0060 mL 2.0120 mL 5.0301 mL
    20 mM 0.1509 mL 0.7545 mL 1.5090 mL 3.7726 mL
    25 mM 0.1207 mL 0.6036 mL 1.2072 mL 3.0180 mL
    30 mM 0.1006 mL 0.5030 mL 1.0060 mL 2.5150 mL
    40 mM 0.0755 mL 0.3773 mL 0.7545 mL 1.8863 mL
    50 mM 0.0604 mL 0.3018 mL 0.6036 mL 1.5090 mL
    60 mM 0.0503 mL 0.2515 mL 0.5030 mL 1.2575 mL
    80 mM 0.0377 mL 0.1886 mL 0.3773 mL 0.9431 mL
    100 mM 0.0302 mL 0.1509 mL 0.3018 mL 0.7545 mL
    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.

    SB 202190 Related Classifications

    • Molarity Calculator

    • Dilution Calculator

    The molarity calculator equation

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    質量   濃度   体積   分子量 *
    = × ×

    The dilution calculator equation

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    一般には略語で表示されます：C1V1 = C2V2

    濃度 （開始） × 体積 （開始） = 濃度 （終了） × 体積 （終了）
    × = ×
    C1   V1   C2   V2
    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    Keywords:

    SB 202190152121-30-7SB202190SB-202190Organoidp38 MAPKAutophagyApoptosisATPpocketanti-cancerspatiallearningmemorydeficitscolorectalInhibitorinhibitorinhibit

    最近チェックした製品:

    オンラインお問い合わせ

    Your information is safe with us. * Required Fields.

    製品名

    		  

    カスタマ需要量 *

    お名前 *

    		 

    タイトル

    メールアドレス *

    		 

    電話番号 *

    デパートメント

    		 

    組纖名 *

    市区町村

    都道府県

    国或いは地域 *

    		      

    必ず会社名を記載ください。個人への返信は行いません。

    備考

    バルクお問い合わせ

    Inquiry Information

    製品名:
    SB 202190
    製品番号:
    HY-10295
    数量:
    MCE 日本正規代理店:

    カスタマーレビュー

    Thank You for Your Feedback!

    Request for HNMR Report

    Please fill out this form to request the QC report. We will send it to your Email address shortly.

    Your information is safe with us. * Required Fields.

    製品名

    		  

    Lot #

    お名前 *

    		 

    メールアドレス *

    電話番号 *

    		 

    部門 *

    組纖名 *

    		 

    国或いは地域 *

    備考

    Request for HNMR Report

    We have received your request and will respond to you as soon as possible.